dc.contributor.author | Hizal, M. | |
dc.contributor.author | Bilgin, B. | |
dc.contributor.author | Paksoy, N. | |
dc.contributor.author | Açıkgöz, Ö. | |
dc.contributor.author | Sezer, A. | |
dc.contributor.author | Gürbüz, M. | |
dc.contributor.author | Ak, N. | |
dc.contributor.author | Yücel, Ş. | |
dc.contributor.author | Ayhan, M. | |
dc.contributor.author | Erol, C. | |
dc.contributor.author | Demirkıran, A. | |
dc.contributor.author | Mandel, N.M. | |
dc.contributor.author | Shbair, A. | |
dc.contributor.author | Gökmen, İ. | |
dc.contributor.author | Başoğlu, T. | |
dc.contributor.author | Paydaş, S. | |
dc.contributor.author | Demiray, A.G. | |
dc.contributor.author | İriağaç, Y. | |
dc.contributor.author | Şakalar, T. | |
dc.contributor.author | Zeynelgil, E. | |
dc.contributor.author | Tatlı, A.M. | |
dc.contributor.author | Bahçeci, A. | |
dc.contributor.author | Güven, D.C. | |
dc.contributor.author | Caner, B. | |
dc.contributor.author | Can, A. | |
dc.contributor.author | Gülmez, A. | |
dc.contributor.author | Karakaş, Y. | |
dc.contributor.author | Yalçın, B. | |
dc.contributor.author | Demirkazık, A. | |
dc.contributor.author | Bilici, A. | |
dc.contributor.author | Aydıner, A. | |
dc.contributor.author | Yumuk, P.F. | |
dc.contributor.author | Şendur, M.A.N. | |
dc.date.accessioned | 2022-10-06T12:54:23Z | |
dc.date.available | 2022-10-06T12:54:23Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 01715216 (ISSN) | |
dc.identifier.uri | http://hdl.handle.net/11616/72187 | |
dc.description.abstract | Introduction: Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods: This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results: Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3–4 adverse events were seen in 11.7% of the patients. Conclusion: Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | |
dc.source | Journal of Cancer Research and Clinical Oncology | |
dc.title | The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study |
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |